Toyobo Co., Ltd. Diagnostic System Dept. of Osaka at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair

Toyobo Co., Ltd. Diagnostic System Dept.

2-2-8, Dojima-Hama, Kita-ku, 530-8230 Osaka

Telephone +81 6 6348-3335
Fax +81 6 6348-3833

This company is co-exhibitor of
Spinreact S.A.U

Hall map

MEDICA 2017 hall map (Hall 3A): stand 3AE23

Fairground map

MEDICA 2017 fairground map: Hall 3A

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.04  Enzymes

Our products

Product category: Enzymes

N-Acetylneuraminic acid aldolase

Code: NAL-301
Origin: Microorganism
Grade: III
Activity: 15 U/mg-solid or more

More Less

Product category: Enzymes

Cholesterol esterase

Code: COE-302
Origin: Schizophyllum commune
Grade: III
Activity: 2.0 U/mg-solid or more

More Less

Product category: Enzymes


Code: DAD-311
Origin: Microorganism
Grade: III
Activity:500 U/mg-solid or more

More Less

Product category: Enzymes


Code: PEO-301
Origin: Horseradish
Grade: III
Activity:110 PU (RZ ≥ 2.0)

More Less

Product category: Enzymes


Code: URH-201
Origin: Jack bean
Grade: II
Activity:100 U/mg-solid or more

More Less

About us

Company details

Toyobo has overcome the crisis of deteriorating performance stemming from the global recession, and is seeking to regain growth. Over the past year our earnings capacity has steadily recovered, and now we are shifting our priority to achieving growth.
In light of the new business environment, Toyobo recently formulated a new medium-term management plan to be implemented through the fiscal year ending March 2014. The vision is for Toyobo to become “the category leader, continuing to create new value that contributes to society in the environment, healthcare, and high-function product fields.” A “category leader” is a business that overwhelmingly dominates in a specific market or field as a result of a company’s unique technologies and expertise. We will expand our strong businesses both in Japan and abroad, and work to generate the next categoryleading businesses. We anticipate 8% annual growth in our specialty businesses, and will continue to manage the textiles and other businesses with an emphasis on asset efficiency. We expect the specialty business fields to account for 75% of sales by fiscal 2014, establishing a high-earning business portfolio.

More Less